203 related articles for article (PubMed ID: 31244382)
1. Repurposing of FDA-approved drugs to target MurB and MurE enzymes in
Rani J; Silla Y; Borah K; Ramachandran S; Bajpai U
J Biomol Struct Dyn; 2020 Jun; 38(9):2521-2532. PubMed ID: 31244382
[TBL] [Abstract][Full Text] [Related]
2. In Silico Drug Repurposing Approach: Investigation of
Ngidi NTP; Machaba KE; Mhlongo NN
Molecules; 2022 Jan; 27(3):. PubMed ID: 35163931
[No Abstract] [Full Text] [Related]
3. Exploring the interaction mechanism between potential inhibitor and multi-target Mur enzymes of mycobacterium tuberculosis using molecular docking, molecular dynamics simulation, principal component analysis, free energy landscape, dynamic cross-correlation matrices, vector movements, and binding free energy calculation.
Kumari M; Singh R; Subbarao N
J Biomol Struct Dyn; 2022; 40(24):13497-13526. PubMed ID: 34662260
[TBL] [Abstract][Full Text] [Related]
4. Drug targeted virtual screening and molecular dynamics of LipU protein of Mycobacterium tuberculosis and Mycobacterium leprae.
Kaur G; Pandey B; Kumar A; Garewal N; Grover A; Kaur J
J Biomol Struct Dyn; 2019 Mar; 37(5):1254-1269. PubMed ID: 29557724
[TBL] [Abstract][Full Text] [Related]
5. Screening of Antitubercular Compound Library Identifies Inhibitors of Mur Enzymes in
Eniyan K; Rani J; Ramachandran S; Bhat R; Khan IA; Bajpai U
SLAS Discov; 2020 Jan; 25(1):70-78. PubMed ID: 31597510
[TBL] [Abstract][Full Text] [Related]
6. A multidrug efflux protein in Mycobacterium tuberculosis; tap as a potential drug target for drug repurposing.
Dwivedi M; Mukhopadhyay S; Yadav S; Dubey KD
Comput Biol Med; 2022 Jul; 146():105607. PubMed ID: 35617724
[TBL] [Abstract][Full Text] [Related]
7. Identification of novel multitarget antitubercular inhibitors against mycobacterial peptidoglycan biosynthetic Mur enzymes by structure-based virtual screening.
Kumari M; Subbarao N
J Biomol Struct Dyn; 2022 Nov; 40(18):8185-8196. PubMed ID: 33826470
[TBL] [Abstract][Full Text] [Related]
8. Computer aided ligand based screening for identification of promising molecules against enzymes involved in peptidoglycan biosynthetic pathway from Acinetobacter baumannii.
Amera GM; Khan RJ; Pathak A; Jha RK; Muthukumaran J; Singh AK
Microb Pathog; 2020 Oct; 147():104205. PubMed ID: 32353580
[TBL] [Abstract][Full Text] [Related]
9. Structure-based virtual screening, free energy of binding and molecular dynamics simulations to propose novel inhibitors of Mtb-MurB oxidoreductase enzyme.
Nirwan S; Chahal V; Kakkar R
J Biomol Struct Dyn; 2021 Feb; 39(2):656-671. PubMed ID: 31906796
[TBL] [Abstract][Full Text] [Related]
10. Drug repurposing: Fusidic acid as a potential inhibitor of M. tuberculosis FtsZ polymerization - Insight from DFT calculations, molecular docking and molecular dynamics simulations.
Akinpelu OI; Lawal MM; Kumalo HM; Mhlongo NN
Tuberculosis (Edinb); 2020 Mar; 121():101920. PubMed ID: 32279872
[TBL] [Abstract][Full Text] [Related]
11. Virtual screening to identify novel potential inhibitors for Glutamine synthetase of
Kumari M; Subbarao N
J Biomol Struct Dyn; 2020 Oct; 38(17):5062-5080. PubMed ID: 31755360
[TBL] [Abstract][Full Text] [Related]
12. Deep-learning based repurposing of FDA-approved drugs against
Joshi T; Pundir H; Chandra S
J Biomol Struct Dyn; 2022 Nov; 40(18):8420-8436. PubMed ID: 33879017
[No Abstract] [Full Text] [Related]
13. Bioisosteric modification of Linezolid identified the potential
Girase R; Ahmad I; Patel H
J Biomol Struct Dyn; 2024; 42(4):2111-2126. PubMed ID: 37097976
[TBL] [Abstract][Full Text] [Related]
14. A Repurposing Approach for Uncovering the Anti-Tubercular Activity of FDA-Approved Drugs with Potential Multi-Targeting Profiles.
Battah B; Chemi G; Butini S; Campiani G; Brogi S; Delogu G; Gemma S
Molecules; 2019 Nov; 24(23):. PubMed ID: 31795400
[TBL] [Abstract][Full Text] [Related]
15. Bioinformatics approach to prioritize known drugs towards repurposing for tuberculosis.
Brindha S; Vincent S; Velmurugan D; Ananthakrishnan D; Sundaramurthi JC; Gnanadoss JJ
Med Hypotheses; 2017 Jun; 103():39-45. PubMed ID: 28571806
[TBL] [Abstract][Full Text] [Related]
16. Docking-based virtual screening of known drugs against murE of Mycobacterium tuberculosis towards repurposing for TB.
Brindha S; Sundaramurthi JC; Velmurugan D; Vincent S; Gnanadoss JJ
Bioinformation; 2016; 12(8):359-367. PubMed ID: 28275291
[TBL] [Abstract][Full Text] [Related]
17. Structure-based virtual screening, molecular dynamics simulation and MM-PBSA toward identifying the inhibitors for two-component regulatory system protein NarL of
Kumar N; Srivastava R; Prakash A; Lynn AM
J Biomol Struct Dyn; 2020 Jul; 38(11):3396-3410. PubMed ID: 31422761
[TBL] [Abstract][Full Text] [Related]
18. Disruption of Irisin Dimerization by FDA-Approved Drugs: A Computational Repurposing Approach for the Potential Treatment of Lipodystrophy Syndromes.
Flori L; Brogi S; Sirous H; Calderone V
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108741
[TBL] [Abstract][Full Text] [Related]
19. Structure investigation, enrichment analysis and structure-based repurposing of FDA-approved drugs as inhibitors of BET-BRD4.
Wakchaure P; Velayutham R; Roy KK
J Biomol Struct Dyn; 2019 Aug; 37(12):3048-3057. PubMed ID: 30079805
[TBL] [Abstract][Full Text] [Related]
20. Natural phytocompounds physalin D, withaferin a and withanone target L-asparaginase of
Sharma D; Saini R; Mishra A
J Biomol Struct Dyn; 2023 Apr; 41(7):2645-2659. PubMed ID: 35132949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
